Respan Dataset Explorer

I have some more data from this patient over the course of 3 years. Please analyze this data and summarise what it means medically. 
Also, In what ways has this patient's health improved? In what ways has it deteriorated? Are there any dramatic changes? What would you be most concerned about?

In 2022:
Right Carotid artery diameter 6.5 mm
Right carotid artery inner diameter 4.5mm
Right imt 0.8 mm
Right inner imt 0.6 mm
Right bifurcation imt 0.9 mm
Right bifurcation diameter unknown

Left carotid artery diameter 6.3 mm
Left carotid artery inner diameter 4.7 mm
Left imt 0.9 mm
Left inner imt 0.7 mm
Left bifurcation imt 0.9 mm
Left bifurcation diameter unknown

Right vertebral artery diameter 3.1 mm
Left vertebral artery diameter 3.9 mm


In 2023:
Right Carotid artery diameter 6.6 mm
Right carotid artery inner diameter 5.5 mm
Right imt 0.9 mm
Right inner imt 0.8 mm

Left carotid artery diameter 6.3 mm
Left carotid artery inner diameter 5.6 mm
Left imt 0.9 mm
Left inner imt 0.8 mm

Right vertebral artery diameter 3.0 mm
Left vertebral artery diameter 3.8 mm

In 2024:
Right Carotid artery diameter 7.1 mm
Right carotid artery inner diameter 5.4 mm
Right imt 0.7 mm
Right inner imt 0.7 mm
Right bifurcation imt 1 mm

Left carotid artery diameter 7.2 mm
Left carotid artery inner diameter 5.3 mm
Left imt unknown
Left inner imt 0.7 mm

Right vertebral artery diameter 3.5 mm
Left vertebral artery diameter 3.6 mm

Analyzing the provided data over a three-year period (2022 to 2024) reveals changes in the patient's vascular health, specifically in the carotid and vertebral arteries. Here's a summary along with interpretations focusing on improvements, deteriorations, noticeable changes, and potential concerns.

### Summary of Changes

**Carotid Arteries:**
- The diameter of both right and left carotid arteries has increased over the three years, indicating possible vascular remodeling. The right carotid artery's diameter increased from 6.5 mm to 7.1 mm, and the left from 6.3 mm to 7.2 mm.
- IMT (Intima-media thickness), a marker for atherosclerosis, shows mixed changes. The right carotid artery IMT slightly decreased from 0.8 mm to 0.7 mm, potentially suggesting a stabilization or slight regression in plaque burden. However, the right bifurcation IMT increased (0.9 mm to 1 mm), indicating possible progression in atherosclerosis at that site.
- Inner diameters have also increased, more notably in 2023.

**Vertebral Arteries:**
- The diameters of the vertebral arteries fluctuated but generally show a slight increase in the right vertebral artery from 3.1 mm to 3.5 mm and a decrease in the left vertebral artery from 3.9 mm to 3.6 mm. These changes might be less clinically significant but still denote some degree of remodeling.

### Health Improvements

- The slight decrease in the right carotid artery IMT by 2024 suggests either stabilization or a mild improvement in atherosclerotic burden.
- The relatively stable diameter of the left carotid artery over the first year and the minimal changes in vertebral artery diameters might suggest a lack of significant progression in vascular disease in those regions during that period.

### Health Deterioration

- The increase in both right and left carotid artery diameters could suggest vascular remodeling in response to hypertension or other forms of vascular stress.
- The increase in the right bifurcation IMT to 1 mm by 2024 is concerning for localized progression of atherosclerosis.

### Dramatic Changes

- The most noticeable changes are the increases in inner diameters of both carotid arteries detected in 2023 and the increased IMT at the right bifurcation by 2024.

### Primary Concerns

1. **Progression of Atherosclerosis:** The increase in IMT, especially at the bifurcation, is concerning and suggests that atherosclerosis is still actively developing in that region.
2. **Vascular Remodeling:** The increasing diameters of the carotid arteries could indicate compensatory changes due to increased blood pressure or flow, which might reflect underlying hypertension or other cardiovascular risk factors needing management.
3. **Potential for Clinical Events:** Progression in carotid artery atherosclerosis increases the risk of cerebrovascular events, such as transient ischemic attack (TIA) or stroke. The primary concern would be ensuring that the progression of atherosclerosis is managed effectively to mitigate these risks.

### Recommendations for Care

- **Risk Factor Management:** Rigorous control of hypertension, hyperlipidemia, diabetes mellitus, and cessation of smoking (if applicable) are crucial.
- **Follow-Up Imaging:** Regular monitoring with ultrasound imaging to detect further changes in arterial health and atherosclerotic progression.
- **Consultation with a Specialist:** A vascular surgeon or a cardiologist specializing in cerebrovascular disease could provide targeted management strategies and interventions to minimize risk.

In conclusion, while there are signs of possible vascular health stabilization in some areas, the overall picture indicates a progression of atherosclerosis, especially at the carotid bifurcation, and vascular remodeling. The focus should be on comprehensive cardiovascular risk management and close monitoring for any signs of progression or potential complications.

Considering all the data I have provided and the analysis you have done, please give me 10 questions the patient should ask his cardiologist. Rank the questions from most to least important

Based on the information and analysis discussed, here are ten critical questions the patient should consider asking their cardiologist during the next visit, ranked in order of importance:

1. **Given the increase in my carotid artery diameters and changes in IMT over the past few years, what do these changes signify about my cardiovascular health?**
2. **How do the changes in the right bifurcation IMT from 0.9 mm to 1 mm impact my risk for cerebrovascular events, and what preventative measures can we take?**
3. **Are the changes observed in my vertebral arteries clinically significant, and how do they relate to my overall vascular health?**
4. **Considering the progression observed in atherosclerosis markers, what adjustments should be made to my current medication regimen or lifestyle to address these risks effectively?**
5. **Should we consider any additional diagnostic tests or imaging studies to further evaluate my carotid artery health and potential plaque buildup?**
6. **Based on the recent trends in my vascular health, how often should I undergo follow-up imaging or assessments to monitor these changes closely?**
7. **What specific lifestyle modifications do you recommend to help slow down or reverse the progression of atherosclerosis based on my current health status?**
8. **Are there any signs or symptoms I should be especially vigilant about that might indicate worsening cardiovascular health or an impending cerebrovascular event?**
9. **How does my vascular health impact my overall risk for heart disease, and are there any additional heart health screenings you would recommend?**
10. **Given my history and the recent changes in my vascular health, is there a benefit to consulting with a vascular surgeon or another specialist for a second opinion or additional treatment options?**

These questions aim to address the primary concerns related to the progression of atherosclerosis, the implications for the patient's cardiovascular and overall health, and to explore all possible avenues for managing and mitigating risks. Prioritizing an open and informative dialogue with the cardiologist will be crucial in formulating an effective care plan tailored to the patient's specific needs and health status.

Do you think the cardiologist is likely to recommend medication? (I understand the limitations and that you are not the doctor). If so, please list the most likely prescription medications, along with any data about each medication's effectiveness, and potential side effects and risks.

Given the information and the general trends in the management of atherosclerosis and cardiovascular risk factors, a cardiologist might consider recommending medication as part of a comprehensive treatment plan. It's important to keep in mind that any medication decision will be based on a detailed personal and family medical history, current health status, and a thorough risk assessment. Here are some common categories of medications that could potentially be recommended, along with their effectiveness, and common side effects and risks:

### 1. Statins

- **Purpose:** Lower LDL cholesterol ("bad" cholesterol) levels, which can help reduce the risk of heart attacks and strokes. Statins are a key part of managing atherosclerosis.
- **Effectiveness:** Statins have been shown to reduce cardiovascular events by about 25% for every 1 mmol/L reduction in LDL cholesterol.
- **Common Side Effects:** Muscle pain, increased risk of diabetes, liver enzyme elevation.
- **Examples:** Atorvastatin, Simvastatin.

### 2. Antihypertensives

- **Purpose:** Lower high blood pressure, which is a significant risk factor for cardiovascular diseases and can exacerbate atherosclerosis.
- **Effectiveness:** Lowering blood pressure can reduce the risk of stroke by 35-40%, heart attack by 20-25%, and heart failure by more than 50%.
- **Common Side Effects:** Depending on the specific medication, side effects can include fatigue, dizziness, and electrolyte imbalances.
- **Examples:** ACE inhibitors (e.g., Lisinopril), Angiotensin II receptor blockers (ARBs) (e.g., Losartan), Calcium channel blockers (e.g., Amlodipine).

### 3. Antiplatelet Agents

- **Purpose:** Prevent the formation of blood clots, which can reduce the risk of stroke or heart attack.
- **Effectiveness:** Can reduce the risk of stroke by 15-20% in patients with atherosclerosis.
- **Common Side Effects:** Increased bleeding risk, gastrointestinal upset.
- **Examples:** Aspirin, Clopidogrel.

### 4. Anticoagulants

- **Purpose:** Similar to antiplatelet agents but work through a different mechanism to prevent clot formation.
- **Effectiveness:** Effective in preventing strokes, especially in patients with conditions like atrial fibrillation.
- **Common Side Effects:** Bleeding risks are a primary concern.
- **Examples:** Warfarin, Apixaban, Rivaroxaban.

### 5. Beta-blockers

- **Purpose:** Lower blood pressure and heart rate, reducing the heart's workload and improving survival after heart attacks.
- **Effectiveness:** Can reduce cardiovascular mortality and the risk of secondary cardiovascular events.
- **Common Side Effects:** Fatigue, cold extremities, sleep disturbances, and erectile dysfunction.
- **Examples:** Metoprolol, Atenolol.

### Note:
The choice of medication, combination therapy, dosage, and management plan will be highly individualized, considering the patient’s specific condition, risk factors, and potential for side effects. It's essential for patients to discuss the benefits, risks, and alternatives with their cardiologist to make an informed decision that aligns with their health goals and preferences. Regular monitoring for effectiveness and side effects will be an integral part of managing the treatment plan.

Please summarise and critique dr aseem malhotra's views about statins

Dr. Aseem Malhotra is a cardiologist and a vocal critic of the widespread use of statins for primary prevention of cardiovascular disease. His views and criticisms mainly revolve around concerns about the efficacy of statins in individuals without pre-existing heart disease, the potential side effects associated with statin usage, and broader issues regarding conflict of interest within medical research and guideline formulation. Below is a summary of his viewpoints, followed by a critique based on the broader medical and research community perspectives.

### Summary of Dr. Malhotra's Views on Statins:

1. **Questioning Efficacy:** Malhotra has argued that the benefits of statins for primary prevention (in patients without established cardiovascular disease) are overestimated. He points to data suggesting that statins offer minimal reduction in overall mortality risk for these individuals.

2. **Highlighting Side Effects:** He emphasizes the potential side effects of statin therapy, which can include muscle pains and weakness, increased risk of diabetes, and cognitive impairment. Malhotra suggests that these side effects are underreported and may impact the quality of life significantly.

3. **Conflict of Interest:** Malhotra has critiqued the pharmaceutical industry's influence on medical research, guidelines, and prescribing behaviors. He calls for more transparency and independent research to guide clinical recommendations.

4. **Lifestyle Over Medication:** He advocates for a greater focus on lifestyle interventions, including diet and exercise, as more effective and safer strategies for reducing cardiovascular risk compared to widespread statin use.

### Critique:

1. **Efficacy Evidence:** The efficacy of statins, especially in secondary prevention (for those with established cardiovascular disease), is well-documented and supported by a vast body of evidence. For primary prevention, guidelines typically recommend statins based on an individual's overall risk profile, with many trials showing a benefit in reducing cardiovascular events.

2. **Side Effects Consideration:** While acknowledging the existence of side effects is essential, large-scale studies and meta-analyses have generally found that serious adverse effects from statins are rare. The perceived prevalence of side effects may be influenced by factors like the nocebo effect, where expecting negative outcomes increases the likelihood of experiencing them.

3. **Addressing Conflicts of Interest:** While the concern about conflicts of interest in medicine is valid and important, it does not inherently invalidate the extensive research supporting statin use. Efforts are continually made within the scientific community to increase transparency and reduce biases.

4. **Role of Lifestyle Modifications:** There is a consensus that lifestyle changes are critical for managing cardiovascular risk. However, in many cases, lifestyle modifications alone may not be enough to reduce risk adequately, and medication like statins can provide an additional benefit.

In conclusion, Dr. Malhotra's critique of statins contributes to the discussion and highlights the importance of considering benefits and risks in the context of individual patient situations. It also underlines the necessity of lifestyle interventions as a foundational approach to cardiovascular risk reduction. However, the broader medical community supports the use of statins, where indicated, as part of a comprehensive strategy for managing cardiovascular risk, informed by a large body of evidence supporting their efficacy and safety profile. Continuing research, debate, and discussion in this area are vital to refining guidelines and recommendations for statin use.

Are there any reasons why the medications you mentioned might be unsuitable for this patient just taking into account the data I have provided

Based on the data you've provided, which includes observations of changing carotid and vertebral artery measurements over time and a context focused on vascular health, certain considerations might influence the suitability of the mentioned medications for this specific patient. It’s crucial to underline, however, that the absolute suitability of any medication can only be effectively assessed by a healthcare professional, taking into account the full medical history, current health status, other ongoing treatments, and individual risk factors. Here are potential considerations or reasons why some medications might be approached with caution:

### Statins

- **Muscle Symptoms:** Given that statins can cause muscle pain or weakness, which might deter physical activity, their prescription would need careful consideration if the patient already experiences such symptoms.
- **Diabetes Risk:** Statins have been linked to a slightly increased risk of developing diabetes. If the patient is already in a prediabetic state or has significant risk factors for diabetes, this might warrant a more nuanced discussion about the risk-benefit balance.

### Antihypertensives

- **Hypotension Risk:** If the patient has borderline or low blood pressure readings, certain antihypertensive medications could further lower blood pressure, posing risks of hypotension.

### Antiplatelet Agents

- **Bleeding Risk:** As antiplatelet agents increase bleeding risk, they might not be suitable for patients with a history of bleeding disorders, those on other medications that increase bleeding risk, or those undergoing surgeries.

### Anticoagulants

- **High Bleeding Risk:** Similar to antiplatelet agents, anticoagulants carry a risk of significant bleeding. They may be unsuitable for patients with uncontrolled high blood pressure (which can increase the risk of hemorrhagic stroke), a history of bleeding, or specific types of stroke.

### Beta-blockers

- **Asthma or Chronic Obstructive Pulmonary Disease (COPD):** Beta-blockers can exacerbate asthma or COPD; thus, they may need to be avoided in patients with these conditions.
- **Bradycardia:** If the patient already experiences bradycardia, beta-blockers could further slow down the heart rate, potentially to problematic levels.

Given that the specific details about existing conditions or comorbidities weren't provided, the above considerations are speculative and generic. Any decision regarding medication would need a comprehensive evaluation, including the current vascular changes observed, the patient's overall cardiovascular risk profile, tolerability, and personal preferences. The evolving nature of the patient’s vascular health signals a requirement for tailored management, where potential medication benefits are carefully weighed against the risks and side effects in collaboration with healthcare providers.

Are there any specific medications in that list he should avoid? If yes tell me his medical condition that makes you think it might not be appropriate for him

Based on the previously provided information about the patient, there are no explicit details about specific comorbid conditions such as diabetes, hypertension, heart rate issues (e.g., bradycardia), bleeding disorders, liver or kidney impairments, or asthma/COPD that would directly influence the appropriateness of the mentioned medications. Without details on these or other health conditions, it's challenging to definitively say which specific medications should be avoided.

However, considering the focus on vascular health and the changes in carotid and vertebral artery measurements:

1. **If the patient has a history of or is at high risk for bleeding disorders**, medications that increase bleeding risk (such as **antiplatelet agents** or **anticoagulants**) would need to be used cautiously. The decision to prescribe these would depend on a careful evaluation of the risk-benefit ratio by a healthcare provider.

2. **For a patient with documented bradycardia** (if this were known), **beta-blockers**, which can further slow heart rate, might be approached with caution unless the therapeutic benefits outweigh the risks, and the condition being treated is serious enough to warrant their use despite potential exacerbation of bradycardia.

3. **In the case of pre-existing liver or kidney disease** (if present, though not specified), certain medications might require dose adjustments or might be contraindicated due to how they are metabolized or excreted. For example, **statins** are primarily metabolized by the liver, and certain types can pose risks in the context of liver dysfunction.

4. **Should the patient have a predisposition to or existing diabetes**, the potential of **statins** to modestly increase blood sugar levels might be a consideration, though the cardiovascular benefits of statins often outweigh this risk for most patients.

Without specific medical conditions explicitly mentioned in your previous information beyond the vascular changes observed, these considerations remain hypothetical. Any medication regimen needs to be carefully personalized, considering all aspects of the patient's health, potential interactions with other medications, and the overall risk-benefit analysis specific to the patient's clinical scenario.

Given the importance of managing vascular health to prevent cardiovascular events, any medication decisions would focus on optimizing this outcome while minimizing potential adverse effects. It's crucial for these decisions to be made in direct consultation with healthcare providers who have a complete picture of the patient's health status.

I told you earlier that he suffers from bradycardia and has high ldl. Do you not remember?

I appreciate your patience and the reminder. Given the specific context including bradycardia and high LDL levels, let's reassess the considerations for the patient's medication options:

### Bradycardia

This condition, characterized by a slower than normal heart rate, can influence the choice of certain cardiovascular medications:

1. **Beta-Blockers:** These are typically used to manage hypertension, heart failure, and prevent heart attacks. However, they can exacerbate bradycardia by further slowing the heart rate. In patients with bradycardia, beta-blockers should be used with caution, closely monitored, or possibly avoided depending on the severity of the bradycardia and the clinical judgment of the healthcare provider.

2. **Calcium Channel Blockers (such as Diltiazem and Verapamil):** Similar to beta-blockers, certain calcium channel blockers can also reduce heart rate and might be contraindicated in patients with significant bradycardia.

### High LDL

For managing high levels of LDL cholesterol (often referred to as "bad" cholesterol), statins are the cornerstone:

1. **Statins:** These are effective in lowering LDL cholesterol levels and reducing the risk of cardiovascular events. Given the patient's high LDL levels, statins would likely be recommended unless contraindicated for another reason. It's essential to monitor for potential side effects, including muscle symptoms and the rare risk of increased blood sugar levels. People with high LDL and evidence of atherosclerosis (as may be suggested by changes in carotid artery measurements) generally benefit significantly from statin therapy.

Given the patient's conditions:

- The primary concern with statins, which are indicated for high LDL, is the careful monitoring of side effects, rather than a direct interaction with bradycardia. Statins could be considered beneficial for this patient, focusing on cardiovascular risk reduction.
- With bradycardia, careful consideration of beta-blockers and certain calcium channel blockers would be necessary, balancing the benefits of controlling blood pressure and reducing heart workload against the potential risk of exacerbating bradycardia.

For someone with both bradycardia and high LDL, a comprehensive approach that involves lifestyle changes, possibly augmented with statin therapy for LDL management, and a cautious evaluation of other heart rate-lowering medications for other cardiovascular needs, would be recommended. Close monitoring by a healthcare provider, with adjustments as needed based on the patient's response to therapy and any emerging side effects, would be crucial.

Do you remember his age? His nse and progrp results?

Yes, based on the initial details you provided:

- The patient is **67 years old**.
- The patient's test results were as follows:
  - **NSE (Neuron-Specific Enolase):** 19.1 ng/mL
  - **ProGRP (Pro-gastrin-releasing peptide):** 91.1 pg/mL

Given these results and the patient's age:

1. **Age (67 years old):** At this age, the patient is considered to be at a higher risk for cardiovascular diseases and possibly other conditions such as certain types of cancer. The management of his health conditions, including the use of medications, would need to take his age into consideration due to potential age-related changes in drug metabolism and sensitivity, as well as the presence of comorbidities.

2. **Elevated NSE and ProGRP:** These elevated markers may indicate the presence of neuroendocrine tumors, such as small cell lung cancer (SCLC), which require thorough investigation and specialist referral. While these markers are more directly relevant to oncological evaluation and management, understanding the full scope of the patient's health, including the presence of any tumors, is crucial for comprehensive cardiovascular management, especially if cancer treatment may impact cardiovascular health.

In light of his specific age, elevated tumor markers, presence of bradycardia, and high LDL levels, a collaborative approach involving oncology (due to the tumor markers), cardiology (for cardiovascular risk management, including attention to bradycardia and high LDL), and potentially other specialists will be essential for optimizing his health outcomes.

Is it fair to conclude the decreasing of imt is a positive sign of improved vascular health in some aspects, despite the widening of arteries which needs managed primarily by blood pressure controlling?

Yes, your conclusion captures two important aspects of vascular health monitoring through changes in carotid artery characteristics:

1. **Decreasing IMT (Intima-Media Thickness):** A reduction in IMT can indeed be interpreted as a positive sign in the context of vascular health. The IMT is a measurement used to gauge the thickness of the carotid artery's walls and is considered an indicator of atherosclerosis. A decrease in IMT over time could suggest a stabilization or regression of atherosclerotic plaque, which translates to a reduced risk for cardiovascular events such as heart attacks and strokes. This improvement could be the result of various factors, including lifestyle modifications, statin therapy, or better control of cardiovascular risk factors like hyperlipidemia.

2. **Widening of Arteries:** The dilation or increase in the diameter of the carotid arteries can be a more complex sign. Vascular remodeling, or changes in the size and structure of blood vessels, can occur in response to several factors, including hypertension (high blood pressure). Arterial dilatation might reflect adaptive responses to increased blood flow demands or compensatory mechanisms to preserve flow in the presence of arterial stiffening or atherosclerosis. However, in certain contexts, arterial widening can also indicate underlying pathology, such as an aneurysm formation, which would require careful evaluation.

Given these changes:
- **Management of Blood Pressure:** Controlling blood pressure is a cornerstone in managing vascular health, particularly for patients showing signs of vascular remodeling or dilation. Hypertension is a well-known risk factor for the progression of atherosclerosis and related complications. Effective blood pressure control can help mitigate the risks associated with widened arteries and reduce the overall cardiovascular risk.

In summary, the observed decrease in IMT can indeed be seen as a favorable indicator of improving or stable vascular health in specific contexts, reflecting the beneficial outcomes of managing atherosclerotic disease. However, the widening of arteries, particularly if driven by hypertension, underscores the importance of vigilant blood pressure management as part of a comprehensive approach to cardiovascular health.

These vascular changes highlight the need for ongoing monitoring and an integrated management strategy that addresses all modifiable risk factors, including lipid levels, blood pressure, smoking status, diabetes control, and lifestyle factors such as diet and physical activity. Collaboration between the patient and a multidisciplinary healthcare team is essential to tailor interventions that best suit the patient's unique health status and risk profile.

Given Table schema – session id, post id, time_stamp, event_type, percentage. The event type includes start time and end time
Build Sql - Find out whether the post in this session (each post will correspond to several start and end times) is valid to read (threshold is 5 seconds and 80% of the screen proportion are valid to read)

To address this query, we should first understand what constitutes a "valid to read" post based on the given criteria:

1. The difference between the start time and end time of the post reading session should be at least 5 seconds.
2. The percentage of the screen proportion during the reading session should be at least 80%.

Having clarified the conditions, we can approach this query step by step. We'll assume that the `event_type` can differentiate between "start" and "end" events (let's say, 'start' for session start and 'end' for session end), and that the `percentage` column represents the screen proportion occupied by the post.

Since SQL doesn't directly allow us to compare rows (to calculate the time difference between start and end times within each session), we may need to use self-joins or window functions, depending on the capabilities of the SQL engine in use.

This example uses generic SQL with window functions, which are supported by many modern SQL databases:

```sql
SELECT DISTINCT
    a.session_id,
    a.post_id
FROM
    (SELECT *,
            LEAD(time_stamp) OVER(PARTITION BY session_id, post_id ORDER BY time_stamp) AS next_time_stamp,
            LEAD(event_type) OVER(PARTITION BY session_id, post_id ORDER BY time_stamp) AS next_event_type,
            LEAD(percentage) OVER(PARTITION BY session_id, post_id ORDER BY time_stamp) AS next_percentage
     FROM your_table_name
     WHERE event_type = 'start'
    ) a
WHERE
    a.next_event_type = 'end'
    AND TIMESTAMPDIFF(SECOND, a.time_stamp, a.next_time_stamp) >= 5 -- Assuming you're using a SQL version that supports TIMESTAMPDIFF, adjust based on your SQL dialect
    AND a.percentage >= 80
    AND a.next_percentage >= 80;
```

**Explanation**:

- We use a subquery (`a`) with window functions to calculate the `next_time_stamp`, `next_event_type`, and `next_percentage` for each row. This aligns the `start` and `end` events, assuming that each `start` event is directly followed by its corresponding `end` event.
- The `PARTITION BY` clause ensures that these calculations are done within groups of the same `session_id` and `post_id`.
- The conditions in the `WHERE` clause of the outer query make sure that:
    - We only consider rows where the `next_event_type` is 'end', ensuring we're looking at complete sessions.
    - The difference between `time_stamp` (start time) and `next_time_stamp` (end time) is at least 5 seconds.
    - The `percentage` at the start and end (`next_percentage`) is at least 80%.
- We use `DISTINCT` to ensure the unique combinations of `session_id` and `post_id` because our analysis could theoretically surface the same post-session pair more than once if our data or initial assumptions did not perfectly align.

Keep in mind, you may need to adjust the query to fit your database's specific SQL dialect and functions. Also, always validate the approach with some test data to ensure it behaves as expected, especially considering potential edge cases within your dataset.